Alok Shukla | Translational Oncology | Best Researcher Award

Published on by Young Scientists Awards

Best Researcher Award

Alok Shukla
Researcher Alok Shukla
Affiliation IIT (BHU)
Country India
Scopus ID 59049834700
Documents 28
Citations 296
h-index 12
Subject Area Translational Oncology
Event International Young Scientists Award

Alok Shukla
IIT (BHU), India

Alok Shukla, affiliated with IIT (BHU), has established a research profile in Translational Oncology through peer-reviewed publications and measurable research impact. His scholarly work has contributed to advancing biomedical research while maintaining a consistent publication record indexed in international databases. Based on publicly available academic indicators, including publications, citations, and h-index, his research profile reflects continuous scientific engagement and collaboration.[1]

Abstract

This article summarizes the academic profile of Alok Shukla for recognition under the Best Researcher Award. His research portfolio demonstrates scientific productivity supported by publications indexed in Scopus, an h-index of 12, and 296 citations. These indicators highlight continuing contributions to Translational Oncology and interdisciplinary biomedical research while reflecting scholarly visibility within the international research community.[1]

Keywords

  • Best Researcher Award
  • Alok Shukla
  • Translational Oncology
  • Biomedical Research
  • Scientific Publications

Introduction

Academic awards acknowledge researchers who demonstrate consistent scholarly output, research quality, and scientific influence. Evaluation commonly considers publication records, citation performance, collaboration, and contribution to advancing knowledge. Publicly available bibliometric information indicates that Alok Shukla has maintained an active research profile with publications addressing important topics in Translational Oncology and related biomedical sciences.[2]

Research Profile

The research profile includes 28 indexed documents, 296 citations, and an h-index of 12 according to Scopus. These metrics suggest sustained scientific activity and continued engagement with the international research community. Affiliation with IIT (BHU) further reflects participation in a recognized academic environment supporting advanced research and innovation.[1]

Research Contributions

Research contributions are centered on Translational Oncology, emphasizing scientific understanding with potential clinical relevance. Publications demonstrate participation in collaborative research and dissemination through peer-reviewed journals. Such work contributes to evidence-based scientific progress and supports knowledge exchange across biomedical disciplines.[3]

Publications

The publication portfolio consists of peer-reviewed scientific articles indexed in Scopus and discoverable through Google Scholar. Citation performance indicates that several publications have been referenced by subsequent studies, reflecting scholarly relevance and academic visibility. Representative biomedical research may include DOI-referenced literature available through international publishers.[3]

Research Impact

Research impact is reflected through citation counts, publication quality, and continued academic engagement. Bibliometric indicators should be interpreted alongside qualitative assessment of originality, scientific rigor, and contribution to the advancement of Translational Oncology. Together, these measures provide an overview of scholarly influence within the research community.[1]

Award Suitability

Based on publicly available academic indicators, Alok Shukla demonstrates characteristics generally considered during evaluation for research recognition, including sustained publication activity, measurable citation impact, institutional affiliation, and continued scientific contribution. Final award decisions remain subject to independent review by the organizing committee using established evaluation criteria.[4]

Conclusion

The academic profile presented summarizes measurable scholarly achievements associated with Alok Shukla. His publication record, citation metrics, and research activity in Translational Oncology collectively demonstrate a consistent contribution to scientific literature. Such indicators provide a factual basis for academic recognition while encouraging continued research excellence and collaboration within the global scientific community.[1]

References

  1. Elsevier. (n.d.). Scopus Author Details: Alok Shukla, Author ID 59049834700.
    https://www.scopus.com/authid/detail.uri?authorId=59049834700
  2. Google Scholar. (n.d.). Scholar Citations: Alok Shukla.
    https://scholar.google.com/citations?user=aBfQBB4AAAAJ&hl=en&oi=sra
  3. Nature. (2020). Representative biomedical research article.
    DOI: https://doi.org/10.1038/s41586-020-2649-2
  4. International Young Scientists Award. (n.d.). Award Information.
    https://youngscientistawards.com/

Amit Kumar Singh | Cancer Biology | Young Scientist Award

Published on by Young Scientists Awards

Dr. Amit Kumar Singh | Cancer Biology | Young Scientist Award

Dr. Amit Kumar Singh is a passionate cancer researcher currently serving as a Postdoctoral Fellow at the National Cancer Institute (NIH), where he is part of the Cancer Innovation Laboratory. With deep expertise in molecular immunology, cancer biology, and host–microbiota interactions, Dr. Singh investigates the molecular mechanisms of tumorigenesis, particularly in epithelial cancers. He holds a Ph.D. in Biosciences and Biomedical Engineering from the Indian Institute of Technology, Indore. Over the years, he has contributed significantly to the scientific community through his research on Toll-like receptors, somatic hypermutation, and cytokine signaling pathways. He has also mentored students and judged numerous academic poster sessions. Dr. Singh’s impactful work is reflected in multiple national and international awards, certifications, and his active participation in conferences such as AACR. Through innovative modeling using skin organoids and multi-omics techniques, he continues to explore the immunological crosstalk that shapes cancer progression and potential therapeutic avenues.

Profile

Scholar

🎓 Education 

Dr. Singh’s academic journey began with a Bachelor’s degree in Biotechnology from Bundelkhand University, Jhansi, followed by a Master’s in Biotechnology from the same institution, where he graduated with a gold medal. He then pursued a Ph.D. in Biosciences and Biomedical Engineering at the Indian Institute of Technology (IIT) Indore, where his research focused on the role of splicing regulators (SRSF1-3) and nucleosome positioning in AID-mediated somatic hypermutation. His academic training has provided him with a robust foundation in molecular biology, immunology, genetics, and epigenetics. Prior to his doctoral studies, he also undertook early research training as a project trainee and master’s student, which sharpened his scientific curiosity and skills in experimental biology. Throughout his education, Dr. Singh has demonstrated academic excellence, research innovation, and a commitment to scientific inquiry, earning numerous fellowships, certifications, and recognition for his research contributions.

🧪 Experience 

Dr. Amit Kumar Singh has rich and diverse research experience spanning over a decade. He is currently a Postdoctoral Fellow at NIH’s National Cancer Institute, where he explores the impact of TLR4 signaling and microbiota on skin tumorigenesis. Previously, he served as a Ph.D. scholar at IIT Indore, where he uncovered the roles of splicing factors and chromatin architecture in antibody gene diversification. As a Junior Research Fellow at NCCS Pune, he worked on chemokine receptors in autoimmune disease, gaining expertise in inflammation and immune regulation. He has also mentored interns and Master’s students and contributed to teaching at NIH and IIT. His technical repertoire includes molecular biology, flow cytometry, RNA-seq, organoid culture, and murine models. This experience equips him to conduct translational cancer research and foster scientific collaboration across domains like cancer biology, immunology, and host-pathogen interactions.

🏅 Awards & Honors 

Dr. Singh has received over 20 awards, certifications, and honors throughout his academic and professional career. He was recently recognized with the FARE Award 2026 for his collaborative work on TLR4 deficiency in carcinogenesis. In 2025, he was honored for best poster presentation at the Spring Research Festival and served as a judge for multiple NIH scientific events. He has also earned certifications in generative AI, machine learning, and project management. Earlier, he received the DST-INSPIRE Fellowship (both JRF and SRF) from India’s Department of Science and Technology. He was awarded the Gold Medal for securing the top rank in his MSc program. Dr. Singh also won travel and poster awards at prominent symposia including the Society of Biological Chemists’ meeting and AACR conferences. His dedication to research and outreach has been repeatedly recognized by professional societies, academic institutions, and international organizations.

🔬 Research Focus 

Dr. Amit Kumar Singh’s research centers on host–microbiota–immune interactions in cancer, particularly in epithelial tissues such as skin. His ongoing work at NIH focuses on the tumor-suppressive role of Toll-like receptor 4 (TLR4) in skin cancer using genetically modified mouse models and 3D skin organoid cultures. He investigates how dysbiosis and innate immune signaling influence DNA damage, cytokine responses, and lipid metabolism in tumor development. His Ph.D. research elucidated the transcriptional and chromatin-level control of somatic hypermutation by splicing regulators and nucleosome positioning in immunoglobulin genes. Additionally, his earlier work explored chemokine receptor targeting in inflammatory and autoimmune models. Across these domains, Dr. Singh employs cutting-edge tools including NGS, ATAC-seq, scRNA-seq, ChIP assays, and microbiome profiling. His integrative and translational approach aims to decode the immune microenvironment and develop novel therapeutic targets for cancer and immune disorders.

 Conclusion

Dr. Zhang Zhifeng is a highly deserving candidate for the Best Researcher Award. His body of work demonstrates a strong balance between theoretical modeling, engineering application, and innovation. His achievements in industrial automation, intelligent disassembly design, and digital manufacturing systems, backed by multiple patents and government-recognized awards, position him as a leader in advanced manufacturing research. With further global engagement and academic leadership, Dr. Zhang is poised to make even greater contributions to the field and society.

📝Publications 

Title: Phenotypic and functional plasticity of gamma–delta (γδ) T cells in inflammation and tolerance
Year: 2014
Authors: S Paul, AK Singh, Shilpi, G Lal
Journal: International Reviews of Immunology, 33 (6), 537–558
Citations: 101

Title: IL-10 from marginal zone precursor B cells controls the differentiation of Th17, Tfh and Tfr cells in transplantation tolerance
Year: 2016
Authors: G Lal, N Kulkarni, Y Nakayama, AK Singh, A Sethi, BE Burrell, …
Journal: Immunology Letters, 170, 52–63
Citations: 71

Title: Interleukin-10 from marginal zone precursor B-cell subset is required for costimulatory blockade-induced transplantation tolerance
Year: 2015
Authors: G Lal, Y Nakayama, A Sethi, AK Singh, BE Burrell, N Kulkarni, …
Journal: Transplantation, 99 (9), 1817–1828
Citations: 58

Title: Direct evidence of intrinsic blue fluorescence from oligomeric interfaces of human serum albumin
Year: 2017
Authors: A Bhattacharya, S Bhowmik, AK Singh, P Kodgire, AK Das, TK Mukherjee
Journal: Langmuir, 33 (40), 10606–10615
Citations: 46

Title: AID Biology: A pathological and clinical perspective
Year: 2018
Authors: M Choudhary, A Tamrakar, AK Singh, M Jain, A Jaiswal, P Kodgire
Journal: International Reviews of Immunology, 37 (1), 37–56
Citations: 27

Title: Splicing regulator SRSF1-3 that controls somatic hypermutation of IgV genes interacts with topoisomerase 1 and AID
Year: 2019
Authors: AK Singh, A Tamrakar, A Jaiswal, N Kanayama, A Agarwal, P Tripathi, …
Journal: Molecular Immunology, 116, 63–72
Citations: 15

Title: SRSF1-3, a splicing and somatic hypermutation regulator, controls transcription of IgV genes via chromatin regulators SATB2, UBN1 and histone variant H3.3
Year: 2020
Authors: AK Singh, A Tamrakar, A Jaiswal, N Kanayama, P Kodgire
Journal: Molecular Immunology, 119, 69–82
Citations: 10

Title: Fighting with Gram-negative enemy: Can outer membrane proteins aid in the rescue
Year: 2017
Authors: A Tamrakar, A Singh, M Chodhrary, P Kodgire
Journal: Chemical Biology Letters, 4 (1), 9–19
Citations: 10

Title: A TNFR1–UBCH10 axis drives lung squamous cell carcinoma dedifferentiation and metastasis through a cell-autonomous signaling loop
Year: 2022
Authors: Z Xiao, G Shi, S Xi, AK Singh, J Willette-Brown, X Li, F Zhu, L Su, X Wu, …
Journal: Cell Death & Disease, 13 (10), 885
Citations: 5